How to Get Prolia (Denosumab) in Michigan

What Is Prolia (Denosumab) and Why It Is Prescribed

Prolia is a fully human monoclonal antibody that binds and inhibits RANK ligand (RANKL), the protein that activates osteoclast-mediated bone breakdown. By blocking RANKL, denosumab slows bone resorption and increases bone mineral density (BMD). The FDA approved denosumab 60 mg for postmenopausal osteoporosis in 2010, and the approval label covers additional indications including male osteoporosis, glucocorticoid-induced bone loss, and bone loss associated with hormone-ablation therapy in prostate and breast cancer [1].

The key FREEDOM trial (N=7,808 to 36 months) found that denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo [2]. That level of fracture reduction makes denosumab one of the most effective antiresorptive agents currently available for osteoporosis management. The American Association of Clinical Endocrinology (AACE) 2020 guidelines list denosumab as a first-line option for patients at very high fracture risk [3].

Denosumab differs from bisphosphonates in one clinically significant way: the anti-resorptive effect disappears quickly after a missed dose. The Endocrine Society's clinical practice guidelines note that "discontinuation of denosumab without subsequent antiresorptive therapy is associated with rapid bone loss and multiple vertebral fractures" [4]. Continuity of the every-6-month injection schedule is therefore not optional.

Who Qualifies for a Prolia Prescription in Michigan

To qualify for denosumab, a Michigan clinician will typically require at least one of the following: a DXA scan T-score of -2.5 or below at the spine, hip, or femoral neck; a T-score between -1.0 and -2.5 combined with a 10-year FRAX hip fracture probability of 3% or greater, or a major osteoporotic fracture probability of 20% or greater; or a documented fragility fracture. These thresholds align with the National Osteoporosis Foundation (NOF) Clinician's Guide criteria [5].

Patients who have already fractured on an oral bisphosphonate, who cannot tolerate oral medications due to esophageal disease, or who have poor gastrointestinal absorption may be transitioned to denosumab as an alternative first-line agent. Michigan Medicaid (Healthy Michigan Plan) covers denosumab for osteoporosis with a prior authorization demonstrating the clinical criteria above.

Absolute contraindications include hypocalcemia. Pre-existing hypocalcemia must be corrected before the first injection. Patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² are at heightened risk of severe hypocalcemia and require closer monitoring, though the drug is not absolutely contraindicated in chronic kidney disease [6].

Required Labs Before Starting Denosumab in Michigan

Labs are non-negotiable before the first injection. Your prescriber will order the following panel, and most telehealth platforms handling denosumab in Michigan require results uploaded before the prescription is finalized.

Serum calcium (corrected for albumin). Hypocalcemia is the most common serious adverse effect of denosumab [7]. The FDA-approved label states that serum calcium must be in the normal range prior to each dose [1]. A corrected serum calcium below 8.5 mg/dL is a contraindication to proceeding.

25-hydroxyvitamin D. Deficiency amplifies hypocalcemia risk. Most prescribers target a 25-OH vitamin D level above 30 ng/mL before initiating therapy. The NOF recommends 1,000 to 1 to 200 mg of calcium daily and 800 to 1 to 000 IU of vitamin D3 as adjunctive therapy throughout denosumab treatment [5].

Serum creatinine and eGFR. As noted, patients with eGFR <30 mL/min/1.73 m² need an individualized calcium-monitoring plan. The FREEDOM extension data showed increased hypocalcemia events in the CKD subgroup [8].

CBC with differential. Denosumab modestly suppresses immune function via RANK/RANKL inhibition in lymphocytes. The FDA label flags serious skin infections (cellulitis) as a risk, making a baseline CBC useful for identifying pre-existing cytopenias [1].

Some Michigan prescribers add bone turnover markers (serum CTX or P1NP) at baseline and at 3 to 6 months to confirm the antiresorptive response, consistent with the Endocrine Society guidance on monitoring pharmacotherapy for osteoporosis [4].

How to Get a Prolia Prescription in Michigan: Step-by-Step

Getting denosumab in Michigan follows a predictable path. The exact timeline depends on whether you go through an in-person specialist, a primary care physician, or a telehealth provider, but the clinical steps are the same.

Step 1. Confirm the diagnosis. Obtain a DXA scan if you do not already have one. Most Michigan radiology groups and hospital systems offer DXA scans with a physician order. Results are typically available within 48 hours and report T-scores at the lumbar spine (L1-L4) and total hip.

Step 2. Schedule an evaluation. An MD, DO, NP, or PA licensed in Michigan may prescribe denosumab. Specialists who most commonly prescribe it include endocrinologists, rheumatologists, and gynecologists (for postmenopausal women). Many primary care physicians in Michigan also manage osteoporosis and are comfortable prescribing denosumab. Under Michigan's telehealth laws (Michigan Public Health Code, Section 333.16285), a telehealth provider may prescribe Schedule and non-schedule medications after conducting a proper evaluation, which means a full history and review of diagnostic data is sufficient without a mandatory in-person visit.

Step 3. Complete your lab work. Your prescriber will submit lab orders to a Michigan LabCorp, Quest Diagnostics, or hospital lab. Results usually return within one to two business days.

Step 4. Handle prior authorization if required. Commercial insurers and Michigan Medicaid routinely require PA for denosumab. Your prescriber's office submits a PA request with your DXA report, FRAX score, relevant clinical history, and a statement of medical necessity. PA turnaround for non-urgent cases is typically three to five business days. Peer-to-peer review can shorten denials.

Step 5. Obtain and administer the injection. Prolia 60 mg is supplied as a single-use prefilled syringe. It is not self-administered at home by most patients; it is given subcutaneously in the upper arm, upper thigh, or abdomen by a healthcare provider every 6 months. Michigan options include your prescribing clinician's office, a specialty infusion center, a retail pharmacy with injection services (select CVS MinuteClinic and Walgreens Health locations in Michigan offer this), or a visiting nurse.

Telehealth Prescribing for Denosumab in Michigan

Telehealth prescribing of denosumab is permitted in Michigan. A Michigan-licensed provider can evaluate you via a synchronous audio-video visit, review your uploaded DXA and lab results, and transmit the prescription electronically to a Michigan pharmacy or specialty pharmacy that coordinates delivery of the prefilled syringe.

Several national telehealth platforms that hold Michigan licenses now offer full osteoporosis management, including denosumab. The HealthRX clinical team sees Michigan patients for initial osteoporosis evaluation and denosumab follow-up via video visit. The workflow runs as follows: the patient books a telehealth visit, uploads a DXA report and recent labs, completes the visit (typically 30 to 45 minutes for an initial consultation), and then receives an electronic prescription. The prescription goes to the patient's pharmacy of choice or a specialty pharmacy that can ship the prefilled syringe in a temperature-controlled package to a Michigan address.

The HealthRX Denosumab Access Framework for Michigan patients involves four checkpoints before injection: (1) confirmed T-score or fragility-fracture criterion, (2) corrected calcium within normal limits, (3) 25-OH vitamin D above 30 ng/mL or active supplementation plan, and (4) PA approval or documented patient-pay agreement. No injection is scheduled until all four are cleared.

Telehealth has been shown to increase access to specialty osteoporosis care. A 2021 analysis in the Journal of Bone and Mineral Research found that telehealth visits for osteoporosis management were non-inferior to in-person visits for treatment initiation rates and 12-month adherence [9]. Michigan's relatively lower density of endocrinologists in rural counties, including the Upper Peninsula and the northern Lower Peninsula, makes telehealth particularly useful for denosumab access in those areas.

Prior Authorization for Denosumab in Michigan: What to Expect

Prior authorization is required by most payers in Michigan, including Blue Cross Blue Shield of Michigan (BCBSM), Priority Health, Aetna Michigan, and Michigan Medicaid. The PA request must generally include:

• A DXA report showing T-score of -2.5 or below (or T-score -1.0 to -2.5 with qualifying FRAX score or prior fracture).
• Documentation of at least one prior trial of, or contraindication to, an oral bisphosphonate (alendronate or risedronate) for many commercial plans.
• A statement of current serum calcium within normal limits.
• ICD-10 diagnosis code: M81.0 (age-related osteoporosis without pathological fracture) is the most commonly used code for postmenopausal osteoporosis in Michigan PA submissions.

BCBSM's medical policy for denosumab (Policy #: 05.00.621, updated 2024) specifically states that coverage requires a T-score at or below -2.5 at the spine or hip, or a T-score between -1.0 and -2.5 with an increased fracture risk per FRAX plus a contraindication or inadequate response to bisphosphonate therapy [10]. Your prescriber should have a PA coordinator submit these documents. If the initial request is denied, the appeal success rate for osteoporosis biologics at peer-to-peer review is reported to be approximately 60 to 70% in published managed care literature [11].

Michigan Pharmacy Access and 503A Compounding

The branded Prolia 60 mg/mL prefilled syringe is available through most Michigan specialty pharmacies, as well as large retail chains. Specialty pharmacies that commonly dispense denosumab in Michigan include Walgreens Specialty Pharmacy, CVS Specialty, and Shields Health Solutions (which contracts with several Michigan health systems).

503A pharmacies and compounded denosumab. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific preparations. Michigan-licensed 503A pharmacies may prepare compounded denosumab formulations when a prescriber documents a clinical need that cannot be met by the FDA-approved product. The FDA does not currently list denosumab on its drug shortage list, which means a 503A pharmacy would need documented patient-specific rationale (such as an allergy to an excipient in the branded product) to compound denosumab [12]. For the vast majority of Michigan patients, the Amgen Prolia prefilled syringe is the appropriate product.

Amgen's PROLIA SUPPORT program (formerly "Prolia Reimbursement Assistance") offers co-pay assistance for commercially insured patients and a free drug program for uninsured or underinsured patients who meet income criteria [13]. Michigan patients can enroll by calling 1-800-772-6436 or through a prescriber's office.

Dosing, Administration, and What Happens at the Injection Visit

The approved dose of denosumab for osteoporosis is 60 mg subcutaneous every 6 months. The injection is given by a healthcare provider, not self-administered. The syringe should be at room temperature for 15 to 30 minutes before injection to reduce discomfort. The preferred injection sites are the abdomen, upper thigh, or upper arm. The injection itself takes under 60 seconds.

All patients starting denosumab should take daily supplemental calcium (1 to 000 mg) and vitamin D (at least 1 to 000 IU) unless hypercalcemia or hypercalciuria contraindicates supplementation, per the FDA label [1] and the AACE/ACE 2020 Postmenopausal Osteoporosis Clinical Practice Guidelines [3].

The FREEDOM long-term extension (10 years, N=2,626 from the original trial) demonstrated continued BMD gains at the lumbar spine (total gain: 21.7%) and total hip (9.2%) with no plateau, supporting long-term use in appropriate patients [14].

Monitoring During Denosumab Treatment

After the first injection, a repeat corrected serum calcium at two to four weeks is recommended for patients with CKD or vitamin D deficiency, per the Endocrine Society clinical practice guidelines on osteoporosis pharmacotherapy [4]. At 6 months (just before the next dose), your clinician should confirm:

• No new hypocalcemia symptoms (perioral tingling, muscle cramps, tetany).
• No new dental procedures planned (jaw osteonecrosis risk is low at 60 mg dosing, approximately 0.04% per patient-year in the FREEDOM trial [2], but the American Dental Association recommends informing your dentist of denosumab use before any invasive dental work [15]).
• Continued calcium and vitamin D supplementation.

DXA is typically repeated at one to two years to assess treatment response. A BMD increase of 3 to 5% at the spine or hip at one year is consistent with a positive response to denosumab [3].

Transferring an Existing Prolia Prescription to Michigan

Patients relocating to Michigan mid-treatment have two concerns: continuity of the 6-month injection schedule and continuity of pharmacy supply. Missing a denosumab dose by more than a few weeks carries a clinically meaningful risk of rebound bone loss and rebound vertebral fractures, as documented in a 2017 JBMR analysis showing multiple new vertebral fractures in 7.1% of patients who discontinued denosumab without follow-on antiresorptive therapy [16].

To transfer your prescription:

1. Ask your prior prescriber for a copy of your complete osteoporosis treatment record, including DXA reports, lab history, and PA approvals.
2. Establish care with a Michigan prescriber (in-person or telehealth) before your next scheduled injection date.
3. Your new Michigan provider can write a new prescription; the drug does not require a formal "transfer" since it is not a controlled substance.
4. Contact your specialty pharmacy about Michigan delivery or obtain a new prescription sent to a Michigan pharmacy.

If your next injection date is within 30 days of your move, contact a Michigan telehealth provider immediately. A telehealth video visit can typically be completed within 48 to 72 hours of booking, and an electronic prescription can be sent the same day.

Cost and Insurance Coverage in Michigan

The average wholesale price (AWP) of Prolia 60 mg is approximately $1,300 to $1,400 per syringe (two syringes per year). With commercial insurance and a PA approval, patient out-of-pocket costs typically range from $0 to $100 per injection after co-pay assistance.

Michigan Medicaid covers denosumab for osteoporosis under the Michigan Drug Benefit formulary with a PA. The PA criteria align with the clinical thresholds described above. Michigan Medicare Part B covers the injection when administered in a physician's office, which is the most common setting; denosumab is billed as a medical benefit (not a pharmacy benefit) under Part B when given in-office [17]. Medicare Part D covers the drug when dispensed by a pharmacy for at-home administration, though most osteoporosis patients receive the injection in a clinical setting.

For patients without insurance or who face a coverage gap, the Amgen Patient Assistance Program provides Prolia at no cost to patients meeting income guidelines (generally at or below 500% of the federal poverty level) [13].